학술논문
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022
Document Type
Original Paper
Author
Yoshinami, Tetsuhiro; Nozawa, Kazuki; Yokoe, Takamichi; Ozaki, Yukinori; Nishio, Hiroshi; Tsuchihashi, Kenji; Ichihara, Eiki; Miura, Yuji; Endo, Makoto; Yano, Shingo; Maruyama, Dai; Susumu, Nobuyuki; Takekuma, Munetaka; Motohashi, Takashi; Ito, Mamoru; Baba, Eishi; Ochi, Nobuaki; Kubo, Toshio; Uchino, Keita; Kimura, Takahiro; Kamiyama, Yutaro; Nakao, Shinji; Tamura, Shinobu; Nishimoto, Hitomi; Kato, Yasuhisa; Sato, Atsushi; Takano, Toshimi
Source
International Journal of Clinical Oncology. 29(6):681-688
Subject
Language
English
ISSN
1341-9625
1437-7772
1437-7772
Abstract
Backgroud: Granulocyte colony-stimulating factor (G-CSF) is widely used for the primary prophylaxis of febrile neutropenia (FN). Two types of G-CSF are available in Japan, namely G-CSF chemically bound to polyethylene glycol (PEG G-CSF), which provides long-lasting effects with a single dose, and non-polyethylene glycol-bound G-CSF (non-PEG G-CSF), which must be sequentially administrated for several days.Methods: This current study investigated the utility of these treatments for the primary prophylaxis of FN through a systematic review of the literature. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two reviewers. A qualitative analysis or meta-analysis was conducted to evaluate six outcomes.Results: Through the first and second screenings, 23 and 18 articles were extracted for qualitative synthesis and meta-analysis, respectively. The incidence of FN was significantly lower in the PEG G-CSF group than in the non-PEG G-CSF group with a strong quality/certainty of evidence. The differences in other outcomes, such as overall survival, infection-related mortality, the duration of neutropenia (less than 500/μL), quality of life, and pain, were not apparent.Conclusions: A single dose of PEG G-CSF is strongly recommended over multiple-dose non-PEG G-CSF therapy for the primary prophylaxis of FN.